A phase II open-label trial of bardoxolone in patients with other rare forms of CKD, including autosomal dominant polycystic kidney disease, IgA nephropathy, CKD associated with type 1 diabetes, and focal segmental glomerulosclerosis

Trial Profile

A phase II open-label trial of bardoxolone in patients with other rare forms of CKD, including autosomal dominant polycystic kidney disease, IgA nephropathy, CKD associated with type 1 diabetes, and focal segmental glomerulosclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Renal failure
  • Focus Therapeutic Use
  • Acronyms PHOENIX
  • Most Recent Events

    • 10 Nov 2017 New trial record
    • 06 Nov 2017 The Company anticipates that data from the individual cohorts of PHOENIX will be released throughout the second half of 2018 and 2019, according to a Reata Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top